Dr. Jim Tananbaum: Scientist, Investor, Genius

Dr. Jim Tananbaum attended Yale University, Harvard Medical School and the Massachusetts Institute of Technology (MIT). He earned a B.S. and B.S.E.E. from Yale, an M.D. from Harvard, an M.S. from MIT an M.B.A from Harvard, and a Master’s of Science (M.S.) M.S. from MIT.

Dr. Jim Tananbaum invests in the health and pharmaceutical sectors with 25 years of being a healthcare entrepreneur and investment strategist. He is strategic in his investments with the goal to build franchise healthcare enterprises.

With so many business opportunities at his fingertips, he founded and is the CEO and Managing Director of Foresite Capital, which provides growth capital to healthcare innovators that seek to transform patient care.

Dr. Tananbaum could not do this all alone. He sought the mentoring of his partners. Rick Levin from Yale, Rick Klausner from the National Cancer Institute, Roy Vagelos, from Merck and Theravance, Bob Gunderson, Gunderson Detmer and George Whitesides, Harvard

Dr. Tananbaum invested and invested in 10x Genomics, Intarcia Therapeutics, Aerie Pharmaceuticals and Aimmune Therapeutics and Amira Pharmaceuticals. He founded two pharmaceuticals, GelTex Pharmaceuticals and Amira Pharmaceuticals and co-founded and was the CEO of Theravance, Inc. and its spin-off Theravance Biopharma, Inc.

His healthcare investment experience also included being a partner at Sierra Ventures, where he established healthcare services investment practice. He also was a founding partner of Prospect Venture Partners II and III, which specialized in investments in healthcare and biotechnology. You can visit Forbes to know more.

Dr. Tananbaum has done well in his investments. For instance, GelTex was acquired for $1.6 billion in 1998. Its primary drug, Renagel (Renzela), initially earned more than $200 million annual revenue. Renzela’s value now is estimated to be close to $1 billion in annual income. He also has several more significant investments such as Intarcia Therapeutics innovative treatment for diabetes and Puma Biotechnology and Aimmune, a food allergy immunotherapy treatment, which will produce a multi-million dollar, return on Foresite Capital investments which led a Series B round of $80 million in 2015.

Dr. Tananbaum goal is to find the brightest thought-provoking leaders in healthcare and to provide them with the means to make decisive scientific discoveries to have a maximum impact on healthcare. More details can be found on Ideamensch.

See more: http://www.fiercebiotech.com/venture-capital/foresite-capital-reloads-a-450m-biotech-venture-fund

Check out the website officialjimtananbaum.com